


**Conclusions:** Hyperbilirubinemia increases the risk of developing AKI by up to 4 times. The useful biomarker for AKI was NGAL Grouped Bar Graph: mean value of bilirubin and NGAL in patients with AKI



<https://doi.org/10.1016/j.aohep.2023.101228>

#### P- 42 METABOLIC ASSOCIATED FATTY LIVER DISEASE AND BODY COMPOSITION MEASUREMENT

Maria Auxiliadora Nogueira, Priscila Flores, Debora Vieira, Rosa Leonora Salerno, Mariana Sophia Almeida Santos, Julio Alves, Maria Eduarda Costa, Aline De Araújo Sousa, Giovanna França, Pedro Cavalcanti De Albuquerque Lemos, Caroline Ramos

Medicina Clínica, Universidade Federal Fluminense, Niteroi, Brasil

**Introduction and Objectives:** Metabolic associated fatty liver disease (MAFLD) is a metabolic and liver disorder with a prevalence of 30% and with significant potential to progress to hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis and hepatocellular carcinoma. Visceral obesity is a risk factor for MAFLD and associated with disease severity. Previous studies have shown that anthropometric measures such as body mass index (BMI), neck circumference (NC), waist circumference (WC), waist-hip ratio (WHR) and body fat percentage (%BF) are predictors of MAFLD. We aimed to assess the prevalence of MAFLD and the role of anthropometric measurements as predictors and its association with liver fibrosis.

**Materials and Methods:** Adults over 18 years old assisted in Antonio Pedro's University Hospital, with risk of MAFLD (pre-diabetes, diabetes mellitus, metabolic syndrome, and obesity). Patient's clinical information, anthropometric, metabolic profiles were assessed. Non-invasive assessment of MAFLD was performed by ultrasound, elastography and bioelectrical impedance analysis (BIA).

**Results:** The group consisted of 73 subjects with 80.8% females. All data are presented as median (IQR) or n (%). Median age was 63 (53-67) years. The prevalence of obesity was 57.5%. Higher diabetes and dyslipidemia (69.8% and 65.7%, respectively). Hepatic steatosis was present in 79.4% of patients. Higher averages for the anthropometric measures that reflect visceral body fat were observed: NC 37.1 cm; WC 104.5 cm; BMI 31.4 kg/m<sup>2</sup> in individuals with hepatic steatosis than those without the disease (NC median 35.7 cm; WC 95.5 cm; BMI 25.7 kg/m<sup>2</sup>). The frequency of liver fibrosis (F 2) was 23.2%. Anthropometric measures had no association with fibrosis, except % BF measure calculated by the BIA (p < 0.02).

**Conclusions:** Anthropometric measurements of visceral obesity, demonstrate to be an important risk factor for MAFLD. BIA a non-

invasive and easily carried out method, could be useful as a screening test to identify individuals with MAFLD.

<https://doi.org/10.1016/j.aohep.2023.101229>

#### P- 43 HCV TESTING AND TREATMENT IN FOUR BRAZILIANS' CORRECTIONAL SETTINGS

Joao Batista da Silva<sup>1</sup>, Eric Soares<sup>1</sup>, Alexandre Munhoz<sup>1</sup>, Raquel Dalpaz Dias<sup>2</sup>, Ana Paula Moraes da Silva Barrufi<sup>2</sup>, Janieri Rosso Dassoler<sup>2</sup>, Tiane Ramos do Canto<sup>2</sup>, Thaís Alves Martins Candido<sup>2</sup>, Maria da Penha da Rosa<sup>3</sup>, Cleber Monteiro Ávila<sup>3</sup>, Eder Gonçalves Portes<sup>3</sup>, Fabiana de Brida<sup>2</sup>, Patricia Rodrigues Oenning<sup>2</sup>

<sup>1</sup> Comm Ops, GILEAD SCIENCES, Florianopolis, Brasil

<sup>2</sup> Complexo Penal Masculino, Osorio, Brasil

<sup>3</sup> Complexo Penal, Osorio, Brasil

**Introduction and Objectives:** The unfavorable hygiene conditions and inadequate health monitoring in many prisons increase the risk of infections such as HIV, syphilis, tuberculosis, and hepatitis B or C. The prevalence of hepatitis C in prisoners worldwide was estimated to be 17.7% (1). Variable access to correctional healthcare resources, limited funding, high inmate turnover rates, and deficient follow-up care after release are a few factors that confound HCV control and prevention in this group. In Brazil, The Criminal Execution Law 7210 of July 11, 1984, in Article 14, grants inmates preventive and curative medical, dental, and pharmacological healthcare. This study aimed to investigate the prevalence of hepatitis C antibodies (HCV-ab) among the 4-prison population in Brazil's South region.

**Materials and Methods:** Participants were interviewed and opt-out provided blood samples and underwent rapid HCV testing and confirmatory testing when indicated. Persons with chronic infection were referred to treatment inside the correctional facility.

**Results:** In 2022, from October to December, 2,057 inmates were tested in 4 correctional facilities in Santa Catarina and Rio Grande do Sul State, with an overall prevalence of 2,52% (52/2,057), 3 times higher than in the general population in Brazil. In the prison with a higher number of tests (762) 95% of the inmates are female, the mean age of 34 y/o, and the HCV-ab prevalence (2,49%) was similar to males' prisons (2,54%).

**Conclusions:** It is necessary to control HCV in prisons by screening and treating prisoners to reach WHO 2030 elimination goals. Diagnosis of chronic HCV in correctional settings followed by linkage to care and successful antiviral treatment can ultimately reduce the risk of liver-related and extrahepatic complications and potentially decrease HCV transmission in correctional facilities and the community after release.

<https://doi.org/10.1016/j.aohep.2023.101230>

#### P-44 OUTCOMES AND MORTALITY OF PATIENTS WITH HEPATOPULMONARY SYNDROME AT A QUATERNARY LIVER TRANSPLANT CENTER

Marcus Vinícius De Acevedo Garcia Gomes, Diogo Delgado Dotta, Juliana Marquezi Pereira, Roque Gabriel Rezende Lima, Evandro de Souza Oliveira, Luiz Augusto Carneiro D'Albuquerque, Carlos Viana Poyares Jardim, Patricia Kittler Vitorio,